GoodRx (NASDAQ:GDRX – Get Rating) had its price objective increased by Royal Bank of Canada from $6.50 to $11.00 in a report issued on Tuesday, The Fly reports. The firm currently has a sector perform rating on the stock.

A number of other equities analysts have also recently commented on GDRX. Bank of America assumed coverage on GoodRx in a report on Monday, June 6th. They set a buy rating and a $11.00 target price for the company. Wells Fargo & Company reduced their price target on shares of GoodRx from $20.00 to $9.00 in a research report on Thursday, May 12th. Raymond James lowered GoodRx from an outperform rating to a market perform rating in a research report on Tuesday, May 10th. SVB Leerink downgraded GoodRx from an outperform rating to a market perform rating and reduced their target price for the company from $33.00 to $10.00 in a research report on Tuesday, May 10th. Finally, Cowen lowered their price target on GoodRx from $22.00 to $9.00 and set a market perform rating for the company in a report on Monday, June 13th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $16.83.

GoodRx Stock Up 2.6 %

GDRX stock opened at $7.60 on Tuesday. GoodRx has a 12 month low of $5.61 and a 12 month high of $48.05. The company has a debt-to-equity ratio of 0.80, a current ratio of 11.23 and a quick ratio of 16.76. The company has a market capitalization of $3.01 billion, a P/E ratio of -69.09, a price-to-earnings-growth ratio of 22.62 and a beta of 0.77. The firm's fifty day simple moving average is $6.59 and its 200-day simple moving average is $13.75.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently made changes to their positions in the company. AlphaCrest Capital Management LLC boosted its stake in GoodRx by 270.6% during the 2nd quarter. AlphaCrest Capital Management LLC now owns 317,178 shares of the company's stock worth $1,878,000 after purchasing an additional 231,592 shares during the period. Apollon Wealth Management LLC acquired a new position in shares of GoodRx in the second quarter valued at approximately $60,000. UBS Group AG raised its stake in shares of GoodRx by 84.2% during the second quarter. UBS Group AG now owns 489,763 shares of the company's stock worth $2,899,000 after purchasing an additional 223,929 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of GoodRx by 5,493.8% during the second quarter. JPMorgan Chase & Co. now owns 26,906 shares of the company's stock worth $159,000 after purchasing an additional 26,425 shares during the period. Finally, Swiss National Bank acquired a new stake in shares of GoodRx during the second quarter worth $1,022,000. Institutional investors and hedge funds own 52.60% of the company's stock.

About GoodRx

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

See Also

• Get a free copy of the StockNews.com research report on GoodRx (GDRX)
• Can You Guess Which EV Stock Is Beating Tesla ?
• Look at Honeywell for a Steady and Diversified Stock
• Why Invest in High-Yield Dividend Stocks?
• Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
• Find and Profitably Trade Stocks at 52-Week Lows

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.